RNA interference versus antibody-based PCSK9 inhibition for the prevention of cardiovascular disease: a drug-target Mendelian randomization study
Cardiovascular Research · 2025
DOI: 10.1093/cvr/cvaf078 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Cardiovascular Research, 2025. Verfasst von Eloi Gagnon und 15 weiteren Autor:innen. Beteiligte Einrichtung: Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Y-3106, Pavillon Marguerite D'Youville…. Hauptthemen laut MEDLINE: Proprotein Convertase 9, PCSK9 Inhibitors, Cardiovascular Diseases, Serine Proteinase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: the Canadian Institutes of Health Research (CIHR), the Foundation of the IUCPQ.
Abstract (Originalsprache)
Aims
RNA interference therapies targeting liver expression of the gene proprotein convertase subtilisin/kexin type 9 (PCSK9) lower LDL-cholesterol (LDL-C) and apolipoprotein B (apoB) levels. As opposed to monoclonal antibodies, which neutralise PCSK9 circulating protein, their effect on atherosclerotic cardiovascular disease (ASCVD) outcomes is unknown. We used genetic variants in the PCSK9 locus influencing PCSK9 function or gene expression in the liver to determine whether antibodies against PCSK9 and RNA interference therapies could have comparable effects on ASCVD. Methods and results We performed genome-wide genotyping and RNA sequencing of 504 human liver sample and identified a genetic variant (rs472495) explaining 5.6% of liver PCSK9 gene expression to mimic lifelong RNA interference of PCSK9. We used the PCSK9 R46L variant, known to alter PCSK9 function, to model antibody-based PCSK9 inhibition. For each standard deviation decrease in apoB levels, both variants were similarly associated with coronary artery disease risk: (odds ratio [OR] = 0.40, 95% confidence interval [CI]: 0.31–0.51, P = 3.7e–13 for rs472495 which affects liver PCSK9 expression) and (OR = 0.48, 95% CI: 0.43–0.55, P = 1.3e–28 for R46L which affects protein levels). Comparable effects of these two genetic inhibition approaches were observed for aortic stenosis, heart failure, ischemic stroke, Type 2 diabetes and glycemic traits as well as non-alcoholic fatty liver disease and liver enzymes.
Conclusion
For a given reduction in apoB levels, genetically predicted reductions in PCSK9 function (mimicking PCSK9 neutralizing antibodies) and liver PCSK9 gene expression levels (mimicking PCSK9 RNA interference) were comparably associated with a lower risk of coronary artery disease. These genetic data suggest that LDL-C/apoB reductions may provide cardiovascular benefits, regardless of how PCSK9 function is inhibited.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Y-3106, Pavillon Marguerite D'Youville, 2725 chemin Ste-Foy, Québec, QC, Canada G1V 4G5.
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
- Department of Molecular Medicine, Faculty of Medicine, Université Laval, Québec, QC, Canada.
- Department of Molecular Biology, Medical Biochemistry and Pathology, Faculty of Medicine, Université Laval, Québec, QC, Canada.
- Department of Surgery, Faculty of Medicine, Université Laval, Québec, QC, Canada.
- School of Nutrition, Université Laval, Québec, QC, Canada.
ORCID-Profile: Eloi Gagnon, Jérôme Bourgault, Émilie Gobeil, Patricia L Mitchell, Arnaud Girard, Audrey Paulin, Christian Couture, Yohan Bossé, Sébastien Thériault, Patrick Mathieu, Marie-Claude Vohl, André Tchernof, Benoit J Arsenault
Förderung
- the Canadian Institutes of Health Research (CIHR)
- the Foundation of the IUCPQ
Zitieren
APA
Gagnon, E., Gill, D., Bourgault, J., Gobeil, É., Mitchell, P. L., Girard, A., Paulin, A., Couture, C., Bossé, Y., Thériault, S., Mathieu, P., Vohl, M. C., Tchernof, A., Ray, K. K., Kastelein, J. J. P., & Arsenault, B. J. (2025). RNA interference versus antibody-based PCSK9 inhibition for the prevention of cardiovascular disease: a drug-target Mendelian randomization study. Cardiovascular Research. https://doi.org/10.1093/cvr/cvaf078
Vancouver
Gagnon E, Gill D, Bourgault J, Gobeil É, Mitchell PL, Girard A, et al. RNA interference versus antibody-based PCSK9 inhibition for the prevention of cardiovascular disease: a drug-target Mendelian randomization study. Cardiovascular Research. 2025. doi:10.1093/cvr/cvaf078
BibTeX
@article{Gagnon2025,
author = {Gagnon, Eloi and Gill, Dipender and Bourgault, Jérôme and Gobeil, Émilie and Mitchell, Patricia L and Girard, Arnaud and Paulin, Audrey and Couture, Christian and Bossé, Yohan and Thériault, Sébastien and Mathieu, Patrick and Vohl, Marie-Claude and Tchernof, André and Ray, Kausik K and Kastelein, John J P and Arsenault, Benoit J},
title = {RNA interference versus antibody-based PCSK9 inhibition for the prevention of cardiovascular disease: a drug-target Mendelian randomization study},
journal = {Cardiovascular Research},
year = {2025},
doi = {10.1093/cvr/cvaf078}
}
EUVIMED